Saturday 17 October 2026 Export VVOS’s income statement to Excel — free account

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 34.9%, EPS grew 43.6%, free cash flow grew 16.4% and total debt rose 2.79%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.13 0.01 −7.14%

Follow VVOS

Alert me

Market cap: $4.8M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 2/9
Altman Z: −9.08
Beneish M: −1.44
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.81

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 4.80

Revenue 20.90

Net Income (25.63)

Free Cash Flow (19.01)

Net Debt 6.36

Current Ratio 0.21

Debt/Equity (2.04)

P/E ratio 0.00

Fwd P/E (0.48)

P/S ratio 0.11

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 50.48%

Next Y EPS Growth 85.37%

Next Y revenue growth 24.92%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.20%

10-year low 10-year high

EV/Sales against its own 10 years 15.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	6	2	2
Receivables	0	0	2	1
Inventory	—	—	—	—
Other	—	—	—	—
	2	7	4	4

	2023	2024	2025	Q'26
Payables	2	1	2	3
ST’ Debt	—	—	8	8
Other	2	1	1	2
	7	5	18	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	5.95%	2.87%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	5	5	—	—	—
’25	3	4	7	4	17
’24	3	4	4	4	15
’23	4	3	3	3	14
’22	4	4	4	4	16
’21	3	4	5	4	17
’20	3	3	3	3	13

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(4)	(3)	(4)	(4)	(15)
’24	(3)	(3)	(4)	(3)	(13)
’23	(4)	(3)	(3)	(3)	(12)
’22	(6)	(5)	(6)	(3)	(20)
’21	(4)	(4)	(4)	(4)	(16)
’20	0	(1)	(1)	(4)	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(4)	—	—	—
’25	(4)	(4)	(4)	(5)	(18)
’24	(3)	(3)	(4)	(3)	(13)
’23	(4)	(3)	(3)	(3)	(13)
’22	(6)	(5)	(6)	(3)	(21)
’21	(4)	(5)	(4)	(5)	(18)
’20	0	(1)	(1)	(4)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.52)	(0.31)	—	—	—
’25	(0.45)	(0.55)	(0.49)	(0.58)	(2.07)
’24	(1.63)	(0.60)	(0.40)	(0.28)	(2.22)
’23	(1.75)	(4.50)	(1.75)	(3.05)	(11.14)
’22	(6.50)	(8.25)	(6.50)	(5.00)	(26.00)
’21	(4.75)	(4.75)	(6.50)	(8.50)	(24.00)
’20	(5.17)	(2.83)	(3.63)	(12.00)	(35.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	141.00	54.50	8.53	2.73	1.91	1.93	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	360.25	271.50	92.25	74.05	12.75	7.95
People
People	Employees	—	—	—	—	98	167	163	114	109	268
	Revenue/emp, $m	—	—	0.00	0.00	0.13	0.10	0.10	0.12	0.14	0.07
Income, $m
Income, $m	Revenue	—	—	4	11	13	17	16	14	15	17
	Gross margin, %	—	—	55.37	75.99	79.70	74.65	62.52	59.93	60.00	60.44
	EBT	—	—	(8)	(11)	(12)	(20)	(24)	(14)	(11)	(21)
	EBT margin, %	—	—	(222.54)	(94.39)	(92.28)	(120.15)	(148.81)	(98.42)	(74.09)	(121.71)
	Net income	—	0	(8)	(11)	(12)	(20)	(24)	(14)	(11)	(21)
	Depreciation	—	—	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	5.21	23.10	25.38	19.88	17.40	11.32	2.99	1.70
	Earnings	—	—	(12.97)	(21.80)	(35.00)	(24.00)	(26.00)	(11.14)	(2.22)	(2.07)
	Cash flow	—	—	(7.45)	(10.83)	(11.03)	(18.53)	(21.27)	(9.80)	(2.53)	(1.49)
	Capex	—	—	0.00	(0.36)	(0.23)	(2.82)	(1.00)	(0.66)	(0.11)	(0.23)
	Free cash flow	—	—	(7.45)	(11.18)	(11.27)	(21.35)	(22.27)	(10.46)	(2.64)	(1.71)
	Book value	—	—	7.55	(5.97)	32.86	30.07	5.21	0.34	1.58	(0.15)
	Shares, m	—	—	1	0	1	1	1	1	5	10
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	8.76	8.76	5.82	2.83	1.06	1.04	1.43	1.20
	P/B	—	—	0.00	0.00	4.50	1.87	3.55	35.00	2.71	0.00
	EV/Sales	—	—	8.75	8.75	4.53	1.49	0.99	1.08	1.16	1.59
	EV/FCF	—	—	(14.75)	(14.75)	(10.20)	(1.39)	(0.78)	(1.16)	(1.31)	(1.57)
Cash, $m
Cash, $m	Operating cash flow	—	—	(5)	(5)	(6)	(16)	(20)	(12)	(13)	(15)
	Capex	—	—	(1)	0	0	(2)	(1)	(1)	(1)	(2)
	Free cash flow	—	—	(5)	(6)	(6)	(18)	(21)	(13)	(13)	(18)
Balance, $m
Balance, $m	Working capital	—	—	0	(7)	13	20	(1)	(5)	2	(14)
	Total debt	—	—	1	4	1	1	2	—	—	9
	Net debt	—	—	(1)	3	(17)	(23)	(1)	(2)	(6)	7
	Shareholders’ equity	—	—	5	(3)	17	26	5	0	8	(2)
Returns, %
Returns, %	ROA	—	—	(230.11)	(149.21)	(109.42)	(68.75)	(100.59)	(111.11)	(85.62)	(104.71)
	ROIC	—	—	0.00	(2,225.84)	(752,500.00)	(459.22)	(423.39)	0.00	(412.15)	(237.15)
	ROE	—	—	(1,002.20)	(1,248.00)	(257.45)	(95.57)	(157.19)	(521.22)	(266.25)	(648.99)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%	Compare
CODX Co-Diagnostics, Inc.	$5.3M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)	Compare
TBIO Telesis Bio Inc.	$5.3M	— (loss-making)	— (loss-making)	−61.79% (below 0%: shrinking)	n/m	−17.96% (below 0%: shrinking)	64.43%	(349.74%)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)	Compare
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	5.4×	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)	Compare
Median of peers	$5.3M	—	—	+1.14%	—	−6.68%	53.83%	(349.74%)

All 149 Medical Devices stocks →

Vivos Therapeutics, Inc. (VVOS) key facts

Strength: Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024.
Vivos Therapeutics, Inc. (VVOS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VVOS traded at $0.13, a market capitalization of $4.8 million.
Return on equity was −649.0% and debt-to-equity -2.04.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.08 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.